1719-P: Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 25 mg in Patients with Type 2 Diabetes: A 24-Week Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with 28-Week Open-Label Extension
Abstract
Introduction and Objective: Type 2 diabetes mellitus (T2DM) patients inadequately controlled with metformin and empagliflozin require additional therapies to improve glycemic control. This study evaluated the efficacy and safety of anagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, as add-on therapy to metformin and empagliflozin.
Methods: In this multicenter, randomized, double-blind, placebo-controlled phase III trial, we enrolled patients with T2DM inadequately controlled (HbA1c 7.0-11.0%) on metformin (≥1000 mg/day) and empagliflozin (25 mg/day). Patients were randomized 1:1 to receive anagliptin (100 mg twice daily) or placebo for 24 weeks, followed by a 28-week open-label extension. The primary endpoint was change in HbA1c from baseline to week 24.
Results: Of 200 randomized patients (n=97 anagliptin, n=100 placebo; mean age 58.6 years; baseline HbA1c 7.76%), 197 completed primary analysis. At week 24, HbA1c decreased 0.83% in anagliptin group versus 0.03% in placebo (difference -0.80%; 95% CI -0.95 to -0.64; P<0.0001). More patients achieved HbA1c ≤7.0% (60.8% vs. 18.0%; P<0.0001) and ≤6.5% (25.8% vs. 3.0%; P<0.0001). Fasting plasma glucose decreased 11.1 mg/dL in anagliptin versus increased 5.75 mg/dL in placebo (P<0.0001). HOMA-β improved: +10.45 versus -6.02 (P=0.0003). During open-label extension, placebo-treated patients switching to anagliptin achieved similar HbA1c at week 52 (anagliptin: 7.14% vs. original placebo: 7.17%; P=0.60), while anagliptin group…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 200 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.